Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 7,500 Shares of Stock

Posted by Defense World Staff on Apr 19th, 2023

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) CFO Greg Zante sold 7,500 shares of the stock in a transaction on Monday, April 17th. The stock was sold at an average price of $20.00, for a total value of $150,000.00. Following the transaction, the chief financial officer now owns 149,279 shares of the company’s stock, valued at approximately $2,985,580. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Greg Zante also recently made the following trade(s):

On Tuesday, April 11th, Greg Zante sold 56,295 shares of Viking Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $1,013,310.00.
On Monday, April 3rd, Greg Zante sold 30,911 shares of Viking Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $556,398.00.
On Thursday, March 30th, Greg Zante sold 131,029 shares of Viking Therapeutics stock. The stock was sold at an average price of $17.00, for a total value of $2,227,493.00.

Viking Therapeutics Trading Up 3.8 %

Shares of VKTX opened at $20.38 on Wednesday. The company has a market cap of $1.60 billion, a PE ratio of -22.40 and a beta of 0.77. The stock has a 50-day moving average price of $12.93 and a 200-day moving average price of $8.29. Viking Therapeutics, Inc. has a 12-month low of $2.02 and a 12-month high of $20.79.

Viking Therapeutics (NASDAQ:VKTX – Get Rating) last issued its quarterly earnings results on Wednesday, February 8th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.03). As a group, analysts predict that Viking Therapeutics, Inc. will post -0.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on VKTX shares. Oppenheimer increased their price target on Viking Therapeutics from $20.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 28th. Maxim Group raised their target price on Viking Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, March 28th. Truist Financial raised their target price on Viking Therapeutics from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, March 29th. StockNews.com started coverage on Viking Therapeutics in a research note on Thursday, March 16th. They issued a “sell” rating for the company. Finally, Raymond James raised their target price on Viking Therapeutics from $12.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 29th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.89.

Institutional Trading of Viking Therapeutics

A number of large investors have recently modified their holdings of VKTX. Centiva Capital LP bought a new stake in shares of Viking Therapeutics during the 3rd quarter valued at about $29,000. Cetera Advisor Networks LLC purchased a new position in shares of Viking Therapeutics during the 2nd quarter valued at about $36,000. Engineers Gate Manager LP purchased a new position in shares of Viking Therapeutics during the 1st quarter valued at about $37,000. PVG Asset Management Corp purchased a new position in shares of Viking Therapeutics during the 3rd quarter valued at about $40,000. Finally, Virtu Financial LLC purchased a new position in shares of Viking Therapeutics during the 3rd quarter valued at about $46,000. Institutional investors own 34.71% of the company’s stock.

About Viking Therapeutics

(Get Rating)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.